[144] Medpace Holdings, Inc. SEC Filing

Rhea-AI Filing Summary

Medpace Holdings, Inc. (MEDP) – Form 144 filing discloses a planned sale of 41,801 common shares through Fidelity Brokerage Services on or about 07/24/2025. The shares carry an aggregate market value of US$18.94 million, implying an estimated price of roughly US$453 per share. With 28.09 million shares outstanding, the proposed disposition equals approximately 0.15 % of total shares, a relatively small portion of the float.

No other MEDP securities were sold by the same account during the past three months, and the filer certifies the absence of undisclosed adverse information. The document does not reveal the seller’s name, relationship to the company, or whether the trade is under a Rule 10b5-1 plan, leaving limited insight into the motivation behind the sale.

Positive

• Sale represents only ~0.15 % of outstanding shares, indicating minimal dilution or ownership impact.
• No other insider sales reported in the prior three months, reducing concerns of a broader disposal trend.

Negative

• Insider intends to sell US$18.94 million in stock, which can be perceived as a negative sentiment signal.
• Filing omits the seller’s identity and relationship to MEDP, limiting transparency for investors.

Insights

Securities Analyst

TL;DR: $18.9 M sale (0.15 % float) is modest; neutral-to-slightly negative signal given missing seller details.

The filing flags an insider-level disposition but the absolute and relative sizes are small, so dilution and control effects are negligible. Absence of past-90-day sales suggests no ongoing liquidation trend. However, lack of disclosure around the seller and any 10b5-1 plan limits transparency, preventing investors from evaluating whether the move is routine diversification or reflects a less favorable outlook. Until identity and context are clarified, the market impact should remain muted, but risk-averse investors may view any insider sale as a cautionary note.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	41801	18940252.46	28093026	07/24/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/24/2025	Option Granted - 02/28/2020	Issuer			41801	07/24/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Medpace (MEDP) shares are being sold under this Form 144?

The filing covers 41,801 common shares of Medpace Holdings, Inc.

What is the dollar value of the proposed MEDP share sale?

The aggregate market value is approximately US$18.94 million.

What percentage of Medpace’s outstanding shares does the sale represent?

It equates to about 0.15 % of the 28.09 million shares outstanding.

When is the anticipated sale date for the MEDP shares?

The approximate sale date listed is 07/24/2025.

Were any MEDP shares sold by this insider in the past three months?

No; the filing states “Nothing to Report” for prior 3-month sales.

Is the trade linked to a Rule 10b5-1 plan?

The Form 144 does not specify whether the sale is under a 10b5-1 trading plan.